In recent decades we have seen an exponential interest in the implications of integrin receptors
in cancer biology and especially in prostate tumour development. Integrins has been reported to
control multiple mechanisms, such as cell survival, proliferation, differentiation, and migration. Here,
we report the current understanding of the integrin signalling mechanisms in metastatic prostate tumour
development, cross-talks between the primary and metastatic sites on tumour growth, interactions
between tumour cells and tissue microenvironment, and epithelial-mesenchymal transition
(EMT). Finally, this review presents the integrin-based chemotherapeutic agents currently under clinically
consideration and provides an insight into cancer drug development using integrin as a target.